Barclays’s IGM Biosciences IGMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2,800
| Closed | -$3.14K | – | 5602 |
|
|
2025
Q2 | $3.14K | Sell |
2,800
-16,378
| -85% | -$20K | ﹤0.01% | 5009 |
|
|
2025
Q1 | $22.1K | Sell |
19,178
-7,125
| -27% | -$13.3K | ﹤0.01% | 4779 |
|
|
2024
Q4 | $161K | Buy |
26,303
+4,749
| +22% | +$56.4K | ﹤0.01% | 4403 |
|
|
2024
Q3 | $357K | Buy |
21,554
+7,027
| +48% | +$77K | ﹤0.01% | 3975 |
|
|
2024
Q2 | $99.8K | Sell |
14,527
-4,527
| -24% | -$38.7K | ﹤0.01% | 3907 |
|
|
2024
Q1 | $184K | Sell |
19,054
-5,516
| -22% | -$63.9K | ﹤0.01% | 4159 |
|
|
2023
Q4 | $204K | Buy |
24,570
+17,233
| +235% | +$100K | ﹤0.01% | 4407 |
|
|
2023
Q3 | $61.3K | Sell |
7,337
-232
| -3% | -$1.97K | ﹤0.01% | 3784 |
|
|
2023
Q2 | $69.9K | Sell |
7,569
-690
| -8% | -$7.73K | ﹤0.01% | 3699 |
|
|
2023
Q1 | $113K | Buy |
8,259
+2,498
| +43% | +$51.7K | ﹤0.01% | 4109 |
|
|
2022
Q4 | $98K | Buy |
5,761
+3,810
| +195% | +$76.2K | ﹤0.01% | 4234 |
|
|
2022
Q3 | $44K | Sell |
1,951
-7,256
| -79% | -$147K | ﹤0.01% | 3817 |
|
|
2022
Q2 | $166K | Sell |
9,207
-161
| -2% | -$2.87K | ﹤0.01% | 3539 |
|
|
2022
Q1 | $251K | Buy |
+9,368
| New | +$174K | ﹤0.01% | 3279 |
|
Other funds holding IGMS
Barclays's IGMS Position: Q3 2025 in Review
Barclays sold out of IGM Biosciences (IGMS) in Q3 2025, closing a stake of 2,800 shares — an estimated $3.14K sold.
Barclays first reported a position in IGMS in Q1 2022 and held it in 14 quarters. The position peaked at $357K in Q3 2024. 1 fund tracked by Wall St. Rank holds IGMS as of Q3 2025.
- Barclays reported no remaining IGM Biosciences position as of Q3 2025 after selling out during the quarter.
- Barclays sold 2,800 IGM Biosciences shares in Q3 2025, an estimated $3.14K.
- Barclays first reported a position in IGM Biosciences in Q1 2022 and held it in 14 quarters.
- Barclays's IGM Biosciences position peaked at $357K in Q3 2024.
- 1 fund tracked by Wall St. Rank held IGM Biosciences as of Q3 2025.
Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.